Literature DB >> 34272712

Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.

Ken Korzekwa1.   

Abstract

Predicting drug-drug interactions (DDIs) from in vitro data is made difficult by not knowing concentrations of substrate and inhibitor at the target site. For in vivo targets, this is understandable, since intracellular concentrations can differ from extracellular concentrations. More vexing is that the concentration of the drug at the target for some in vitro assays can also be unknown. This uncertainty has resulted in standard in vitro practices that cannot accurately predict human pharmacokinetics. This case study highlights the impact of drug distribution, both in vitro and in vivo, with the example of the drug interaction potential of montelukast.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CYP2C8; Cheng-Prusoff equation; Drug-drug interaction; Fraction unbound; Free drug hypothesis; Microsomal proteins; Montelukast; Protein binding

Year:  2021        PMID: 34272712     DOI: 10.1007/978-1-0716-1554-6_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Comments on Mougey et al. (2009): Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19: 129-138.

Authors:  Xiaoyan Chu; George Philip; Raymond Evers
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

2.  Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  J Pharmacol Exp Ther       Date:  2011-12-21       Impact factor: 4.030

3.  Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics.

Authors:  Swati Nagar; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2012-06-18       Impact factor: 3.922

4.  Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.

Authors:  Markus Fridén; Fredrik Bergström; Hong Wan; Mikael Rehngren; Gustav Ahlin; Margareta Hammarlund-Udenaes; Ulf Bredberg
Journal:  Drug Metab Dispos       Date:  2010-12-13       Impact factor: 3.922

5.  Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement.

Authors:  David Hallifax; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2006-04       Impact factor: 3.922

6.  Impact of pH on plasma protein binding in equilibrium dialysis.

Authors:  Christopher J Kochansky; Daniel R McMasters; Ping Lu; Kenneth A Koeplinger; Haley H Kerr; Magang Shou; Kenneth R Korzekwa
Journal:  Mol Pharm       Date:  2008-03-18       Impact factor: 4.939

7.  Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.

Authors:  Peter J Kilford; Michael Gertz; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2008-04-14       Impact factor: 3.922

8.  Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.

Authors:  Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2004-09       Impact factor: 6.875

9.  Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.

Authors:  Edward B Mougey; Hua Feng; Mario Castro; Charles G Irvin; John J Lima
Journal:  Pharmacogenet Genomics       Date:  2009-02       Impact factor: 2.089

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.